The addition expands the membership of the industry body, which represents manufacturers of generic, biosimilar, and value-added medicines. Moving forward, Athlone Pharmaceuticals will work alongside MFI to advocate for policies that secure medicine supplies, support European manufacturing, and ensure affordable treatments remain accessible to patients in Ireland.
Welcoming the announcement, Head of Athlone Pharmaceuticals Limited, Barry Doyle said: “Joining Medicines for Ireland is a significant milestone for Athlone Pharmaceuticals. We look forward to contributing to the association’s efforts to make affordable medicines accessible to patients in Ireland. As an MFI member, we will advocate for policies that bolster manufacturing in Europe and call for regulations to be viewed through the lens of securing supply for patients.”
